IL2 and cancer: Strategies to protect anti-cancer lymphocytes from inactivation by ROS may therefore be useful in cancer immunotherapies that aim to improve NK cell and T cell functions, as exemplified by the recent introduction of a ROS formation inhibitor, used in conjunction with the NK cell and T cell activating cytokine interleukin-2, for relapse prevention in AML [19], [21].